v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 27, 2024
Dec. 29, 2023
Current assets:    
Cash and cash equivalents $ 258,346 $ 262,994
Marketable securities 930,815 732,308
Trade receivables, net 269,706 237,407
Inventory 21,013 17,323
Prepaid expenses and other current assets 69,838 67,926
Total current assets 1,549,718 1,317,958
Non-current marketable securities 523,421 728,717
Property and equipment, net 124,414 128,731
Deferred tax assets, net 358,869 361,145
Goodwill 63,684 63,684
Right-of-use assets and other non-current assets 340,170 342,122
Total assets 2,960,276 2,942,357
Current liabilities:    
Accounts payable 59,309 33,768
Accrued compensation and benefits 90,605 93,325
Accrued clinical trial liabilities 56,184 71,615
Rebates and fees due to customers 62,495 59,619
Accrued collaboration liabilities 30,030 27,533
Other current liabilities 95,723 108,417
Total current liabilities 394,346 394,277
Non-current portion of operating lease liabilities 194,445 189,944
Other non-current liabilities 96,066 94,224
Total liabilities 684,857 678,445
Commitments and contingencies (Note 10)
Stockholders' equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 285,780 and 302,793 at September 30, 2024, and December 31, 2023, respectively 286 303
Additional paid-in capital 2,361,470 2,440,710
Accumulated other comprehensive income (loss) 3,956 (3,750)
Accumulated deficit (90,293) (173,351)
Total stockholders’ equity 2,275,419 2,263,912
Total liabilities and stockholders' equity $ 2,960,276 $ 2,942,357